NIH Initiative Gains Five New Companies - - BioPharm International

ADVERTISEMENT

NIH Initiative Gains Five New Companies



The National Institutes of Health (NIH) have gained the participation of Abbott, Bristol-Myers Squibb, GlaxoSmithKline, Janssen Pharmaceutical Research & Development, and Sanofi in their effort to advance new therapeutic research.

In May 2102, NIH’s National Center for Advancing Translational Sciences (NCATS) launched the Discovering New Therapeutic Uses for Existing Molecules Program. The program is a collaboration between NIH and industry to match researchers with compounds that have already cleared the development process to test for new therapeutic uses. Participating companies will provide compounds and data determined to meet specific NIH eligibility criteria. Compound preliminary information is available on the NCATS website.

"Each company participating in this innovative collaboration has made substantial research and development investments to advance these compounds to the point where they can be used in clinical studies," states Kathy L. Hudson, NCATS acting deputy director, in a NIH press release. "If researchers funded through this effort can demonstrate new uses for the compounds, they could significantly reduce the amount of time it takes to get a treatment to patients in need."

NCATS plans to provide up to $20 million in fiscal year 2013 to fund cooperative research grants. The NIH press release states that researchers who meet specific milestones will “conduct preclinical validation and clinical feasibility studies in the first stage, and proof-of-concept clinical trials in the second stage, to test whether one of the compounds may be effective against a previously unexplored disease target.”

Pfizer, AstraZeneca, and Eli Lilly have already signed on to the program.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

American CryoStem and Rutgers University File Joint Patent on Stem Cell Platform
April 11, 2014
PhRMA Report Reveals Growth Trajectories and Policy Factors Affecting Biopharmaceutical Growth
April 11, 2014
Center for Biologics Evaluation and Research Relocates
April 11, 2014
FDA Develops Alternative Assay to Increase Availability of Influenza Vaccines
April 10, 2014
Merck Announes Management Changes
April 7, 2014
Author Guidelines

Click here